Cizzle Biotech Share News (CIZ)

IN BRIEF: Cizzle Biotechnology signs lung-cancer study in China

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Signs further Memorandum of Understanding with International Co-Innovation Centre for Advanced Medical Technology for a clinical pilot study with the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Center of China. The clinical pilot study will evaluate optimised assays using a monoclonal antibody that Cizzle Biotechnology has developed that specifically detects CIZ1B, which is highly associated with stage 1 lung cancer.

UPDATE: Cizzle, Vela Technologies notes planned Conduit Pharma merger

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - and Vela Technologies PLC - Bradford, England-based investment firm focused on early-stage and pre-IPO disruptive technology investments - Notes announcement by Conduit Pharmaceuticals Ltd that it intends to become a publicly traded company on the Nasdaq in the US through a merger with special purpose acquisition firm Murphy Cannon Acquisition Corp. The deal is expected to generate USD149.7 million worth of proceeds for Conduit.

Cizzle Biotechnology reports narrowed loss as passes "key milestones"

(Alliance News) - Cizzle Biotechnology Holdings PLC on Wednesday said it had passed "key milestones" as it moved towards generating revenue for its products.

Vela Tech, Cizzle Biotech shares jump on investee's trial results

(Alliance News) - Vela Technologies PLC and Cizzle Biotechnology Holdings PLC on Thursday hailed the latest clinical trial results from investee St George Street Capital Ltd.

Cizzle Biotechnology expands use of lung cancer test

(Alliance News) - Cizzle Biotechnology Holdings PLC on Tuesday said that it is using its early-stage lung cancer test technology to detect more cancer types, notably breast cancer.

UK shareholder meetings calendar - next 7 days

TRADING UPDATES: Valereum opens NFT market; Conygar considers raising

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News:

IN BRIEF: Cizzle Biotechnology widens annual loss on acquisition costs

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Posts higher annual loss in 2021. Pretax loss widens to GBP4.0 million from GBP14,000 in 2020. In May 2021, Cizzle was bought by Bould Opportunities PLC. Acquisition-related costs stand at GBP3.1 million in 2021 versus none in 2020.

AIM WINNERS & LOSERS: SDI upbeat; Westminster rises on contract win

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Friday.

Cizzle Biotechnology shares jump on US lung cancer collaboration

(Alliance News) - Cizzle Biotechnology Holdings PLC on Friday announced a new collaboration into lung cancer testing with a US partner.

TRADING UPDATES: WANdisco bookings up; STM legal appeal denied

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

IN BRIEF: Cizzle Biotech notes promising data from Arcadia study

Cizzle Biotechnology Holdings PLC - London-based diagnostics developer - Reports that Arcadia clinical study shows potential value of AZD1656 treatment for Covid-19 patients. The new data analysis comes from St George Street Capital Ltd, which runs the trial with Excalibur Medicines Ltd for the treatment, in which Cizzle holds a "significant" royalty-bearing economic interest.

Cizzle Biotechnology acquires further 5% interest in Covid treatment

(Alliance News) - Cizzle Biotechnology Holdings PLC shares jumped on Monday after it announced that it acquired an additional 5% interest in the commercialisation of the Covid-19 treatment AZD 1656.

TRADING UPDATES: Alliance Pharma to appeal; Braemar sales to rise

TRADING UPDATES: Alliance Pharma to appeal; Braemar sales to rise

IN BRIEF: Cizzle Biotechnology inks cancer detection partnership

IN BRIEF: Cizzle Biotechnology inks cancer detection partnership